A new comprehensive review published in the World Journal of Pediatrics (DOI: 10.1007/s12519-026-01049-y) has synthesized decades of research to reveal that CHD family proteins—which physically reshape DNA to control gene activity—play distinct, stage-specific roles in heart development. The findings offer a unifying framework that could explain the origins of a wide range of congenital heart defects and improve diagnostic efficiency.
The study, led by a team from China, systematically evaluated evidence from human genetics, animal models, and stem-cell systems. It found that CHD7, the gene most frequently mutated in CHARGE syndrome, plays a dominant role in building the heart's early structure. In contrast, CHD3 and CHD4 act as "identity guardians," ensuring heart cells commit to the correct fate during chamber formation. CHD8 appears to regulate later ventricular growth and functional maturation.
"The data show that we cannot treat these proteins as a single, interchangeable group. They have very distinct, stage-specific jobs," the authors said. "For example, CHD7 is the key player in the early morphogenetic events that build the heart's structure, while CHD4 helps lock in the identity of heart cells as they differentiate."
The review proposes three testable models—parallel, sequential, and compensatory—to guide future research on how these remodelers might cooperate or buffer each other's loss. Although direct proof of coordinated action is lacking, the framework clarifies which gene to prioritize when studying specific heart defects.
The findings have direct implications for clinical practice. For genetic screening, the study provides a clear priority: CHD7 for outflow-tract defects, CHD4 for chamber-patterning anomalies, and CHD8 for ventricular dysfunction. This prioritization can improve diagnostic efficiency. Therapeutically, while directly targeting remodelers is risky due to their broad expression, identifying their downstream pathways—such as those regulating cardiomyocyte proliferation or metabolism—may offer safer drug targets.
Future studies combining time-resolved multi-omics and combinatorial genetics could uncover how these proteins coordinate across development, potentially paving the way for precise, temporally controlled epigenetic therapies. The work was supported by several Chinese funding agencies, including the National Key Research and Development Program of China and the National Natural Science Foundation of China.
